Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer [0.03%]
大规模的荟萃分析和精准功能测定鉴定出FANCM区域，在该区域内PTVs对ER阴性和三重阴性乳腺癌的风险不同
Amandine Billaud,Gisella Figlioli,Clémence Mooser et al.
Amandine Billaud et al.
The breast cancer risk conferred by germline protein truncating variants (PTVs) in known and putative breast cancer genes has been extensively investigated. However, the effect of FANCM PTVs on breast cancer risk remains unclear. Our previo...
Subtype distribution, clinical presentation, and molecular spectrum of neurofibromatosis type 1-associated breast cancer [0.03%]
神经纤维瘤病1型相关乳腺癌的亚型分布、临床表现和分子光谱
Niccolò Di Giosaffatte,Paola Daniele,Francesco Petrizzelli et al.
Niccolò Di Giosaffatte et al.
Aim: To investigate clinical and molecular features of neurofibromatosis type 1 (NF1)-associated breast cancer (BC) in a large multicenter cohort. Methods...
Evaluation of breast cancer screening programmes: Candidate performance indicators and their association with breast cancer mortality [0.03%]
乳腺癌筛查计划的评价：候选绩效指标及其与乳腺癌死亡率的关系
Carlos Canelo-Aybar,Pablo Alonso-Coello,Sergei Muratov et al.
Carlos Canelo-Aybar et al.
Aim: Evaluation of a breast cancer (BC) screening programme is necessary to ensure its quality. Performance measurements might be prioritized considering the association with outcomes related to BC mortality. We piloted a...
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34 [0.03%]
乳腺癌ABCSGⅢ4试验诊断活检标本中ESR1、PGR、ERBB2和MKI67的mRNA表达
Stephanie Kacerovsky-Strobl,Christine Deutschmann,Dominik Hlauschek et al.
Stephanie Kacerovsky-Strobl et al.
Aim: To investigate the performance of the Xpert® Breast Cancer STRAT4 (CE-IVD∗) Assay (STRAT4) in the neoadjuvant, randomized Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 34. ...
Once-weekly ultra-hypofractionated radiation therapy for breast cancer: Outcomes from a single-institution real-world cohort [0.03%]
每周一次的大分割放射治疗治疗乳腺癌：单一机构的真实世界队列结果分析
María Jesús García Anaya,Ángel Calvo Tudela,Jaime Gómez-Millán et al.
María Jesús García Anaya et al.
Background: The purpose of this observational study was to report clinical outcomes in a consecutive series of elderly and/or comorbid patients with early breast cancer treated with once-weekly postoperative whole-breast ...
Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain? [0.03%]
来信：三阴性乳腺癌病理完全缓解：复发的防护盾，但不能防止脑转移？
Gabriel Berlingieri Polho,Yumi Ricucci Shinkado,Leticia Kimie Murazawa et al.
Gabriel Berlingieri Polho et al.
Effectiveness of hybrid digital breast tomosynthesis/digital mammography in women presenting for routine screening at Maroondah BreastScreen, Australia: Interim analysis [0.03%]
澳大利亚墨尔本Maroondah BreastScreen妇女筛查中心行数字乳腺断层合成/常规数字化乳腺摄影的临床效果分析：中期结果报告
M Luke Marinovich,Darren Lockie,Michelle Giles et al.
M Luke Marinovich et al.
Hybrid digital breast tomosynthesis (DBT)/digital mammography (DM) (mediolateral oblique from DBT with synthetic 2D, craniocaudal from DM) can potentially improve breast cancer detection and address longer DBT screen-reading time. This pre-...
Development and validation of prognostic model based on distribution and density of CD3+ and CD8+ infiltrating lymphocytes in breast cancer: A multicenter cohort study [0.03%]
基于乳腺癌中CD3+和CD8+浸润性淋巴细胞分布和密度的预后模型的开发与验证：一项多中心队列研究
Xu Zhang,Zheng Wang,Yiwei Tong et al.
Xu Zhang et al.
Background: The prognostic value of infiltrating lymphocytes distribution and their densities in breast cancer is unknown. This study aimed to develop a tumor immune microenvironment-based model to predict prognosis in ea...
Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial [0.03%]
BRIGHT-2试验中，HR阳性、HER2阴性转移性乳腺癌接受贝罗西利或安慰剂联合氟维司群治疗的动态血液学指标与结局之间的关联研究结果
Hangcheng Xu,Yan Wang,Qiang Sa et al.
Hangcheng Xu et al.
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy have revolutionized the treatment landscape of hormone receptor (HR)-positive advanced breast cancer. However, reliable biom...
Brain imaging screening in metastatic breast cancer: Is it time to rethink clinical guidelines and practice? [0.03%]
转移性乳腺癌的脑成像筛查：是否到了重新审视临床指南和实践的时候了？
Sarah Sammons,Nayan Lamba,Nancy U Lin
Sarah Sammons